ABBV-1088 + itraconazole

**ABBV-1088 + itraconazole** is an experimental drug combination investigated to assess drug-drug interactions, safety, tolerability, and pharmacokinetics in healthy adults. ABBV-1088 is a small molecule inhibitor targeting PTEN-induced kinase 1 (PINK1) and is under early-phase clinical investigation by AbbVie. Itraconazole is a well-established antifungal agent, commonly used for systemic fungal infections, and is also known as a strong inhibitor of CYP3A4, a drug-metabolizing enzyme. The combination is studied mainly to evaluate how itraconazole affects the pharmacokinetics of ABBV-1088, as part of a phase 1 clinical trial in healthy volunteers[1][2][3][4][6][7].